skip to search skip to navigation skip to main content

Archive: 2017

Early detection of prostate cancer is key for increasing survival rate in Morocco

27th November 2017 in Product Launches

  Prostate cancer incidence rate in Morocco has increased by 62% from 2004 to 2007[1] 10-20% of patients are diagnosed at a late stage[2], indicating a need for increased awareness around screening and early detection Astellas launches a new prostate cancer treatment that enables physicians to better tailor prostate cancer disease management based on patients’…

Read Full Post

Early detection is key to increase the survival rate of prostate cancer patients

03rd May 2017 in Product Launches

7% of the Egyptian male population are within the age group at risk for prostate cancer[1] Egyptian men who are diagnosed with prostate cancer are 7.2 times more likely to die from the disease as compared with the USA[2] Astellas Pharma launched Xtandi™ – enabling physicians to better tailor prostate cancer disease management according to…

Read Full Post

Astellas to Acquire Ogeda SA

05th April 2017 in Mergers & Acquisitions

Acquisition expands Astellas’ late stage clinical pipeline with Fezolinetant Tokyo, Japan and Gosselies, Belgium, April 3, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ogeda SA (CEO:Jean Combalbert, ”Ogeda”) announced today that Astellas and Ogeda shareholders have entered into a definitive agreement under which Astellas has agreed to acquire…

Read Full Post

Suffering from ‘got to go now’ feeling – UroGuide launched to offer support to overactive bladder (OAB) patients

12th March 2017 in Other activities

UroGuide and OAB Awareness campaign has been launched to address lack of bladder disease awareness UroGuide is available for download from Lebanese Urology Society website  Failing to seek medical advice results in patients suffering unnecessarily with the burdens of OAB Beirut, 3rd March 2017. Lebanese Urology Society in partnership with Astellas Pharma have developed and…

Read Full Post

GenomeDx Announces Research Collaboration with Astellas to Identify Genomic Drivers of Patient Response to XTANDI® (enzalutamide) Capsules

13th February 2017 in Other activities

San Diego, January 2017 – Astellas in collaboration with GenomeDx Biosciences announced that it has entered into a research collaboration to apply genomic tumor profiling using GenomeDx’s Decipher® Classifier and Decipher GRID® as a potential aid in the identification of prostate cancer patients undergoing active surveillance who may benefit from treatment with XTANDI® (enzalutamide). As…

Read Full Post

Astellas Reports the First Nine Months Financial Results of FY2016

31st January 2017 in Other activities

Astellas Pharma Inc. (TOKYO: 4503) (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced financial results for three quarters of fiscal year 2016 ending March 31, 2017 (“FY2016”). “We achieved many milestones including the acquisition of Ganymed Pharmaceuticals, a Germany-based pharma company, last December. The acquisition of Ganymed will enable Astellas to further expand its oncology…

Read Full Post

Privacy Policy  |  Terms of Use  |  Cookies PolicyCopyright © 2020 Astellas Pharma